Your browser doesn't support javascript.
loading
VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells.
Temerozo, Jairo R; Sacramento, Carolina Q; Fintelman-Rodrigues, Natalia; Pão, Camila R R; de Freitas, Caroline S; Dias, Suelen Silva Gomes; Ferreira, André C; Mattos, Mayara; Soares, Vinicius Cardoso; Teixeira, Lívia; Azevedo-Quintanilha, Isaclaudia G; Hottz, Eugenio D; Kurtz, Pedro; Bozza, Fernando A; Bozza, Patrícia T; Souza, Thiago Moreno L; Bou-Habib, Dumith Chequer.
Afiliación
  • Temerozo JR; Laboratory on Thymus Research, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Sacramento CQ; National Institute for Science and Technology on Neuroimmunomodulation, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Fintelman-Rodrigues N; Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Pão CRR; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil.
  • de Freitas CS; Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Dias SSG; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Ferreira AC; Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Mattos M; Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Soares VC; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Teixeira L; Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Azevedo-Quintanilha IG; Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Hottz ED; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Kurtz P; Iguaçu University, Nova Iguaçu, RJ, Brazil.
  • Bozza FA; Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Bozza PT; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Souza TML; Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil.
  • Bou-Habib DC; Program of Immunology and Inflammation, Federal University of Rio de Janeiro, UFRJ, Rio de Janeiro, RJ, Brazil.
J Leukoc Biol ; 111(5): 1107-1121, 2022 05.
Article en En | MEDLINE | ID: mdl-35322471
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Péptido Intestinal Vasoactivo / COVID-19 Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Leukoc Biol Año: 2022 Tipo del documento: Article País de afiliación: Brasil
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Péptido Intestinal Vasoactivo / COVID-19 Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Leukoc Biol Año: 2022 Tipo del documento: Article País de afiliación: Brasil